Vortex Imaging announced a $12 million financing round on May 18, 2026—money the Israeli-American medical device company will plow into FDA clearance efforts and an eventual commercial launch of a technology that sounds, at first blush, improbable: a handheld ultrasound system that borrows computational tricks from petroleum engineers hunting for oil deposits thousands of feet underground.
The financing round, backed by 10D Ventures, Entrée Capital, Harel T.E.C Partnership, Connecticut Innovations, and PhiFund Ventures, arrives at a moment when the portable ultrasound market is both heating up and consolidating. Handheld devices once dismissed as novelties now command serious attention from hospital systems and primary care clinics seeking diagnostic tools that fit in a coat pocket. Whether geophysics-inspired imaging can break through in that increasingly noisy market remains an open question.
Vortex also announced board changes alongside the capital infusion. Ori Hadomi—who served as CEO of Mazor Robotics before that company's $1.6 billion sale to Medtronic in 2018—joins as Chairman. Chris Cleary, a Medtronic corporate development veteran with prior stints at GE Healthcare, takes a board seat as well, alongside Yahal Zilka from 10D Ventures and Dr. Yael Grunbaum of Entrée Capital. It's the sort of seasoned roster that signals serious ambitions beyond proof-of-concept.
From Seismology to Sonography
The core technology here isn't entirely new—it's borrowed, adapted, and miniaturized. Full Waveform Inversion, the computational engine behind Vortex's flagship Vortex360 device, has for years helped seismologists and oil prospectors map what lies beneath the Earth's crust. Vortex CEO Tomer Ben David, writing on NVIDIA's developer blog last June, laid out the architecture: a compact probe equipped with an embedded NVIDIA Jetson processor captures raw ultrasound data in seconds, then hands off the computational heavy lifting to cloud-based GPUs that iteratively simulate and reconstruct volumetric 3D images.
The pitch, in essence, is standardization—volumetric imaging at the point of care without demanding the specialized training ultrasound typically requires. Sonography has long been operator-dependent, its image quality tethered to the skill of the technician wielding the probe. If Vortex's algorithms can flatten that learning curve, the implications stretch beyond convenience into access, particularly in rural or underserved settings.
Vortex was granted U.S. patent number US 11,559,285 B2 on January 24, 2023, covering reflection ultrasound tomographic imaging via full-waveform inversion. The company's initial clinical bet focuses on urology and nephrology—kidney and urinary tract imaging where three-dimensional visualization could aid diagnosis and guide procedures. Why those specialties? Perhaps because they represent clinical niches where 3D detail matters but where CT and MRI remain overkill for many routine evaluations.
A Crowded, Fast-Moving Field
Vortex is hardly alone in chasing the handheld ultrasound opportunity. Butterfly Network, GE HealthCare, Philips, and Clarius all field portable systems, several with 3D capabilities already baked in. Butterfly won FDA clearance this past March for an AI tool that estimates gestational age from blind-sweep scans—a notable milestone in automating interpretation. Clarius announced it had turned profitable last December while simultaneously clearing six AI models designed to work within its handheld devices. Over in China, SonoStar unveiled its own 3D wireless handheld ultrasound in January.
According to MarketsandMarkets, the portable ultrasound device market is valued at $2.49 billion in 2025 and projected to reach $3.83 billion by 2030. Vortex references a $262 billion addressable market on its LinkedIn page, though that figure encompasses the broader radiology procedures and services market rather than device sales narrowly defined. It's an expansive way to frame opportunity—optimistic, maybe, but not unreasonable if the technology eventually displaces more expensive imaging modalities.
Still, the path from engineering triumph to clinical adoption is littered with well-funded failures. Image quality, clinical workflow integration, reimbursement codes, and physician trust all weigh as heavily as algorithmic elegance. Vortex will need to prove its oil-field mathematics translate not just into pretty pictures but into diagnostic accuracy that holds up under real-world conditions.
The People Behind the Probe
Ben David brings startup experience to the effort—he previously co-founded Rocketick Technologies, a chip design automation firm that Cadence acquired in 2016 after attracting backing from Intel Capital and NVIDIA. Uri Tal, Vortex's co-founder and CTO, comes from the world of high-performance computing and GPU architecture, a background that maps neatly onto the computational demands of full-waveform inversion.
The company, founded in 2020, operates out of dual headquarters in Sunnyvale, California, and Givatayim, Israel. That geographic split isn't unusual for Israeli tech startups—close to Silicon Valley capital and customers on one side, deep engineering talent on the other.
The financing supports advancing FDA clearance, though no specific regulatory submission has been confirmed as of late May, and that regulatory timeline will largely dictate when and how aggressively Vortex can push into hospitals and clinics. Twelve million dollars buys runway, but not infinite patience. The company faces the long, unglamorous work of navigating regulatory review, building out a salesforce, and convincing skeptical physicians that algorithms designed for finding oil can also find kidney stones.
Whether that bet pays off will depend less on the novelty of the underlying math than on execution—how well Vortex can translate subsurface seismology into images clinicians trust enough to act on. The financing gives them a fighting chance to find out.
